SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-030329
Filing Date
2023-03-09
Accepted
2023-03-09 07:30:09
Documents
6
Period of Report
2023-04-06

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm231898-4_def14a.htm DEF 14A 397688
2 GRAPHIC lg_rubiustherapeut-4c.jpg GRAPHIC 84840
3 GRAPHIC px_page01-bw.jpg GRAPHIC 666324
4 GRAPHIC px_page02-4c.jpg GRAPHIC 681609
5 GRAPHIC sg_craigjalbert-bwlr.jpg GRAPHIC 17088
6 GRAPHIC sg_pablojcagnoni-bwlr.jpg GRAPHIC 6748
  Complete submission text file 0001104659-23-030329.txt   2167582
Mailing Address C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035
Business Address C/O VERDOLINO & LOWEY, P.C. 124 WASHINGTON STREET, SUITE 101 FOXBORO MA 02035 617-679-9600
Rubius Therapeutics, Inc. (Filer) CIK: 0001709401 (see all company filings)

IRS No.: 042688109 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38586 | Film No.: 23718196
SIC: 2836 Biological Products, (No Diagnostic Substances)